Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population

•Metronomic adjuvant capecitabine improved the survival outcomes in NPC patients.•Adjuvant capecitabine chemotherapy fails to favor all subgroup patients.•Plasma EBV DNA might predict the suitable population for adjuvant chemotherapy.

Saved in:
Bibliographic Details
Published in:Oral oncology 2022-01, Vol.124, p.105544-105544, Article 105544
Main Author: Wang, Bi-Cheng
Format: Article
Language:English
Subjects:
Chemotherapy, Adjuvant
Humans
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Neoplasms - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Metronomic adjuvant capecitabine improved the survival outcomes in NPC patients.•Adjuvant capecitabine chemotherapy fails to favor all subgroup patients.•Plasma EBV DNA might predict the suitable population for adjuvant chemotherapy.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2021.105544